GNOM
Start your own research on GNOM after you read my entire report. I think you will agree that this company is in an industry that has huge growth potential.
GNOM develops and commercializes a DNA sequencing platform for human genome sequencing and analysis.
Complete Genomics has a proprietary DNA sequencing platform that allows the company to conduct large-scale DNA sequencing studies for paying customers, so that these customers (universities, medical companies, and researchers) don't need to buy their own expensive machines.
GNOM recently came off a 52wk low of $2.55, and with a 52wk high of $18.55 it has a huge trading range.
View Chart: http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=GNOM&insttype=Stock
Couple this with recent insider buying which accounted for roughly 16% of the float, and a back log of orders based on their latest earnings report. GNOM could be the comeback kid for the new year.
Peter Lynch, famed Wall Street manager once said that, "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the shares will rise."
The company recognized revenue for over 700 genomes compared to over 300 genomes recognized in the third quarter of 2010
"The company continues to make progress in expanding its order book as well as its customer base. In the third quarter, we signed orders for approximately 3,400 genomes valued at approximately $17 million," said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics.
"We have booked orders for approximately 6,100 genomes valued at $31 million from the beginning of the year through September 30, 2011, with more than 100 customers having now used our service."
The company's backlog as of September 30, 2011 was approximately $24 million and 4,800 genomes. The company ended the third quarter of 2011 with $105.1 million in cash, cash equivalents and short-term investments.
Fourth Quarter 2011 Outlook
The company shipped approximately 2,400 genomes to its customers in the three quarters of 2011. In the fourth quarter, the company expects to ship between 900 and 1,200 genomes, bringing the total shipments for the year to between 3,200 and 3,600
Did you know that a body contains millions of complete duplicates of itself? From the moment of conception, every cell's nucleus contains a tiny cluster of 24 chromosomes, strands of genetic code perfectly sequenced to determine everything about a particular individual.
Called a genome, this bundle of information consists of genes, a sequence of only four chemicals arranged in endless combinations, kind of like the countless sequencing of binary codes making up computer programs. Nearly 25,000 different genes consisting of over 3 billion of these chemical building blocks make-up a human being.
Researchers have mapped the entire human genome with implications beyond measure. By understanding how each piece of genetic code relates to some specific aspect of the body, scientists are then able to manipulate that code. This is the science of "genomics" and medical research is its primary beneficiary. The potential benefits of genetic mapping are staggering to consider.
Mapping genomes is an extremely complex process. The highest levels of biological research standards are required to ensure a complete and uncorrupted report. Companies that supply high quality genome mapping are at the forefront of medical research and in huge demand.
Complete Genomics, Inc. (GNOM), established in 2005 by a trio of experts.
One of these is Dr. Radoje Drmanac, a founding pioneer of genomics. He also developed what GNOM's website describes as "a massively parallel sequencing technique called 'sequencing by hybridization'." Dr. Drmanac's extensive knowledge is a primary catalyst for the company's meteoric growth within this small and unique industry.
GNOM's stated goal is "to provide academic and biopharmaceutical researchers with complete human genomic data and analysis at an unprecedented quality, cost and scale without requiring researchers to invest in in-house sequencing instruments, high- erformance computing resources and specialized personnel."
The impact of genetics on diseases is not a straightforward process where gene A causes disease B. Instead, many genes combine to influence a person's susceptibility to specific diseases and drug protocols.
Untangling the subtle complexities of these effects is what genetic research is all about. This effort will someday lead to dramatic, long-awaited cures and even prevention methods to diseases currently killing and disabling millions of people worldwide.
Some of the diseases being researched using GNOM's services include cancer, Mendelian diseases and rare variant diseases.
Very large quantities of genetic samples are required and the challenge overcome by GNOM was reducing the huge expense underlying large-scale genomic studies. They have done this by developing their own unique and "completely new set of data management and analytics capabilities."
GNOM has combined their cost-effective methodologies with sequencing that is 99.999% accurate. This level of precision and cost-effective processes has attracted the attention of research facilities worldwide.
What specifically does Complete Genomics do to generate revenue? Researchers ship sample material to GNOM's sequencing center, where they are sequenced and analyzed.
In roughly 60 days these researchers are provided with "finished, research-ready data, enabling them to focus exclusively on their single highest priority, discovery." This spares them massive expenses because according to the company they can "offload to us the complex processes of sample preparation, sequencing, computing and data storage and management."
Start your own research on GNOM at: http://www.completegenomics.com Always do your own research and consult with your own financial professional.
